Synonymous mutations have long been ignored in cancer studies since they don’t affect the amino acid sequences of proteins. But research increasingly reveals that they can have disease-driving effects.
“Silent” Mutations Make Noise In Cancer
“Silent” Mutations Make Noise In Cancer
Synonymous mutations have long been ignored in cancer studies since they don’t affect the amino acid sequences of proteins. But research increasingly reveals that they can have disease-driving effects.
Synonymous mutations have long been ignored in cancer studies since they don’t affect the amino acid sequences of proteins. But research increasingly reveals that they can have disease-driving effects.
Although epigenetic changes were long thought to largely act on the genome, rather than as part of it, research is now showing that these patterns can, directly or indirectly, change the genetic code.
Evidence is mounting that epigenetic marks on DNA can influence future generations in a variety of ways. But how such phenomena might affect large-scale evolutionary processes is hotly debated.
Alejandra Manjarrez, PhD | Oct 14, 2022 | 5 min read
A team proposes that the addition of a small accessory subunit to the carbon-fixing enzyme was key to improving its catalytic properties and specificity to CO2.
Off the western Australian coast, in Shark Bay, a field of seagrass big enough to cover Washington, DC, has flourished for more than four millennia, a new study finds.
Analyzing the whole genome sequences of more than 18,000 tumors, researchers catalog nearly 60 new patterns of mutations that could inform cancer treatment.
A first-of-its-kind gene therapy dramatically reduced misfolded protein levels in some clinical trial participants for up to six months and reduced levels in all participants for up to a year.
Angie Voyles Askham, Spectrum | Feb 3, 2022 | 3 min read
The genes are involved in pacing the development of inhibitory and excitatory neurons. An imbalance in these two types of signaling is thought to play a role in autism.
The SARS-CoV-2 variant was first detected in January, but its rising prevalence and potential resistance to vaccines has garnered it special attention from the World Health Organization.
The FDA pauses the research program on a lentivirus-based treatment for a rare neurological condition after a patient developed a bone marrow disorder that could presage leukemia.